Floatz logo

Eflornithine

Colorectal Neoplasm

SWOG Cancer Research NetworkSmall moleculePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

117 Active assets in the Colorectal Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BBB
Eloxatin
Peking University Cancer Hospital & Institute
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Nottingham University Hospitals NHS Trust
Phase 4BBB
Irinotecan
Shanghai Zhongshan Hospital
Phase 4BBB
Regorafenib
Sergey Orlov, MD
Phase 4BB

View all 50 →

Same molecule, other indications

Eflornithine is also rated in:

classic familial adenomatous polyposisDormant
BB
Indicative ·
66 / 100
View asset →
precancerous conditionDormant
BB
Indicative ·
64 / 100
View asset →
colon adenomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →